Statement: Less than 5% of patients undergoing the intervention in the primary trial had adverse events, in comparison almost 10% patients in cohort 1 of the secondary trial  experienced an adverse event, and more than 30% of those in cohort 2 of the secondary trial had adverse events.
Primary_evidence: Adverse Events 1:   Total: 4/95 (4.21%)   Death not associated with CTCAE term - Death NOS 1/95 (1.05%)   Death - Disease progression NOS 2/95 (2.11%)   CNS cerebrovascular ischemia 1/95 (1.05%)
Secondary_evidence: Adverse Events 1:   Total: 3/31 (9.68%)   Edema: limb * 2/31 (6.45%)   Neutrophils/granulocytes (ANC/AGC) * 0/31 (0.00%)   Cardiac General - Other (Specify, __) *  [1]0/31 (0.00%)   Cardiac General - Other (Specify, __) *  [2]0/31 (0.00%)   Left ventricular diastolic dysfunction * 0/31 (0.00%)   Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia * 0/31 (0.00%) Adverse Events 2:   Total: 8/25 (32.00%)   Edema: limb * 1/25 (4.00%)   Neutrophils/granulocytes (ANC/AGC) * 0/25 (0.00%)   Cardiac General - Other (Specify, __) *  [1]1/25 (4.00%)   Cardiac General - Other (Specify, __) *  [2]0/25 (0.00%)   Left ventricular diastolic dysfunction * 1/25 (4.00%)   Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia * 0/25 (0.00%)